Pharmacogenetic aspects of therapy for autoimmune hepatitis against the background of degenerative-dystrophic joint lesions
DOI:
https://doi.org/10.15584/ejcem.2025.3.7Keywords:
autoimmune hepatitis, betaine-homocysteine methyltransferase, one-carbon metabolism genes, personalized therapyAbstract
Introduction and aim. The pathogenesis of autoimmune diseases, including musculoskeletal, gastrointestinal, and endocrine manifestations, involves the interaction of genotype and environmental factors. Pathologies demonstrate comorbidity and clinical heterogeneity even within a single family. Genetic polymorphisms of one-carbon metabolism are key regulators of cellular processes that become therapeutic targets.
Description of the case. The study describes personalized therapy for a patient with an autoimmune comorbid disease, with an emphasis on genetic and metabolic characteristics. The treatment regimen is adapted to the features of the one-carbon metabolism profile of a patient with chronic autoimmune hepatitis and degenerative-dystrophic joint disease. Family history includes autoimmune thyroiditis, vitiligo, Parkinson’s disease, cardiovascular diseases. The patient’s genotype for single nucleotide polymorphisms rs1801133, rs1801131, rs1801394, rs1805087, and rs3733890 of the one-carbon metabolism genes is associated with elevated plasma homocysteine levels. After treatment, changes in biochemical parameters were observed: alanine aminotransferase (72→53 U/L), aspartate aminotransferase (53→44 U/L), gamma-glutamyltransferase (129→89 U/L), alkaline phosphatase (313→125 U/L) and homocysteine (15.1→17.0 μmol/L).
Conclusion. Positive dynamics after personalized therapy demonstrates the importance of an interdisciplinary approach to etiopathogenetic treatment, emphasizing the need to support hepatobiliary function along with muscular and skeletal therapy.
Downloads
References
Floris M, Moschella A, Alcalay M, et al. Pharmacogenetics in Italy: current landscape and future prospects. Hum Ge-nomics. 2024;18(1):78. doi: 10.1186/s40246-024-00612-w
Popoviciu MS, Kaka N, Sethi Y, et al. Type 1 Diabetes Mel-litus and Autoimmune Diseases: A Critical Review of the Association and the Application of Personalized Medicine. J Pers Med. 2023;13(3):422. doi: 10.3390/jpm13030422
Conti L, Galli G, Ligato C, et al. Autoimmune atrophic gastritis and coeliac disease: A case–control study. Dig Liver Dis. 2023;55(1):69-74. doi: 10.1016/j.dld.2022.07.001
Massironi S, Gallo C, Elvevi A, et al. Incidence and preva-lence of gastric neuroendocrine tumors in patients with chronic atrophic autoimmune gastritis. World J Gastrointest Oncol. 2023;15(8):1451-1460. doi: 10.4251/wjgo.v15.i8.1451
Katsumata R, Kamada T, Murao T, et al. A Case of Au-toimmune Gastritis and Hepatitis with Enlarging Gastric Polyps after Reducing the Dose of Prednisolone. Case Rep Gastroenterol. 2023;17(1):117-123. doi: 10.1159/ 000529151
Kunovsky L, Dite P, Jabandziev P, et al. Autoimmune Dise-ases of Digestive Organs–A Multidisciplinary Challenge: A Focus on Hepatopancreatobiliary Manifestation. J Clin Med. 2021;10(24):5796. doi: 10.3390/jcm10245796
Antonelli A, Benvenga S. Editorial: The Association of Other Autoimmune Diseases in Patients With Thyroid Autoimmunity. Front Endocrinol (Lausanne). 2018;9:540. doi: 10.3389/fendo.2018.00540
Suzuki A, Hayashi K, Hayashi M, et al. A Case of Auto-immune Polyendocrine Syndrome Type 3B and Peripheral Neuropathy Due to Thiamine Deficiency. Cureus . 2024;16(1):e52123. doi: 10.7759/cureus.52123
Betterle C, Sabbadin C, Scaroni C, et al. Autoimmune Polyendocrine Syndromes (APS) or Multiple Autoimmune Syndromes (MAS). In: Colao A, Jaffrain–Rea ML, Beckers (eds). Polyendocrine Disorders and Endocrine Neopla-stic Syndromes. Endocrinology. Springer, Cham. 2019. doi: 10.1007/978–3–319–73082–0_1–1
Lahner E, Conti L, Cicone F, et al. Thyro–enterogastric autoimmunity: pathophysiology and implications for pa-tient management. Best Pract Res Clin Endocrinol Metab. 2020;34(1):101373. doi: 10.1016/j.beem.2019.101373
Higuchi T, Oka S, Furukawa H, et al. Genetic risk factors for autoimmune hepatitis: implications for phenotypic heterogeneity and biomarkers for drug response. Hum Ge-nomics. 2021;15(1):6. doi: 10.1186/s40246–020–00301–4
Barliana MI, Afifah NN, Amalia R, et al. Genetic Poly-morphisms and the Clinical Response to Systemic Lupus Erythematosus Treatment Towards Personalized Medicine. Front Pharmacol. 2022;13:820927. doi: 10.3389/ fphar.2022.820927
Ceballos FC, Chamizo-Carmona E, Mata-Martín C, et al. Pharmacogenetic Sex-Specific Effects of Methotrexate Response in Patients with Rheumatoid Arthritis. Pharmaceutics. 2023;15(6):1661. doi: 10.3390/pharmaceutics15061661
Zhang Q, Lin J, Zhang Z, et al. MTHFR Polymorphism and Folic Acid Supplementation Influence Serum Homocyste-ine Levels in Psoriatic Patients Treated with Methotrexate. Clin Med. 2022;11(15):4580. doi: 10.3390/jcm11154580
Zhu J, Wang Z, Tao L, et al. MTHFR Gene Polymorphism Association With Psoriatic Arthritis Risk and the Efficacy and Hepatotoxicity of Methotrexate in Psoria-sis. Front Med (Lausanne). 2022;9:869912. doi: 10.3389/ fmed.2022.869912
Fedota O, Roschenyuk L, Tyzhnenko T, et al. Methotrexate effect on biochemical indices of psoriasis patients depends on MTHFR gene polymorphism. Ukr Biochem J. 2020;92(1):66-74. doi: 10.15407/ubj92.01.066
Fedota O, Roschenyuk L, Tyzhnenko T, et al. Pharmacogenetic effects of methotrexate (mtx) in ukrainian patients depending on the mthfr genotypes (clinical cases). Georgian Med News. 2018;279:111-117.
Ni G, Qin J, Li H, et al. Effects of antiepileptic drug monotherapy on one–carbon metabolism and DNA methylation in patients with epilepsy. PLoS One. 2015;10(4):e0125656. doi: 10.1371/journal.pone.0125656
Hwang Y, Yun HJ, Jeong JW, et al. Co-inhibition of glu-taminolysis and one–carbon metabolism promotes ROS accumulation leading to enhancement of chemotherapeutic efficacy in anaplastic thyroid cancer. Cell Death Dis. 2023;14(8):515. doi: 10.1038/s41419–023–06041–2
George AK, Majumder A, Ice H, et al. 2020. Genes and genetics in hyperhomocysteinemia and the “1–carbon metabolism”: implications for retinal structure and eye functions. Can J Physiol Pharmacol. 2020;98(2):51-60. doi: 10.1139/cjpp–2019–0236
van Vliet MM, Schoenmakers S, Gribnau J, et al. The one– carbon metabolism as an underlying pathway for placen-tal DNA methylation – a systematic review. Epigenetics. 2024;19(1):2318516. doi: 10.1080/15592294.2024. 2318516
Steluti J, Carvalho AM, Carioca AAF, et al. Genetic Variants Involved in One–Carbon Metabolism: Polymor-phism Frequencies and Differences in Homocysteine Concentrations in the Folic Acid Fortification Era. Nutrients. 2017;9(6):539. doi: 10.3390/nu9060539
Tinelli C, Di Pino A, Ficulle E, et al. Hyperhomocysteinemia as a Risk Factor and Potential Nutraceutical Target for Certain Pathologies. Front Nutr. 2019;6:49. doi: 10.3389/ fnut.2019.00049
McCaddon A, Miller JW. Homocysteine–a retrospective and prospective appraisal. Front Nutr. 2023;10:1179807. doi: 10.3389/fnut.2023.1179807
Ducker GS, Rabinowitz JD. One–Carbon Metabolism in Health and Disease. Cell Metab. 2017;25(1):27-42. doi: 10.1016/j.cmet.2016.08.009
Huang X, Li D, Zhao Q, et al. Association between BHMT and CBS gene promoter methylation with the efficacy of folic acid therapy in patients with hyperhomocysteine-mia. J Hum Genet. 2019;64(12):1227-1235. doi: 10.1038/ s10038–019–0672–7
Arumugam MK, Paal MC, Donohue TM Jr, et al. Beneficial Effects of Betaine: A Comprehensive Review. Biology (Basel). 2021;10(6):456. doi: 10.3390/biology10060456
Fedota O, Puzik N, Skrypkina I, et al. Single nucleotide polymorphism C994g of the cytochrome P450 gene possess pleiotropic eff ects in Bos taurus, L. Acta Biologica Szegediensis. 2022;66(1):7-15. doi: 10.14232/abs.2022.1.7–15
Pascale RM, Simile MM, Calvisi DF, et al. S–Adeno-sylmethionine: From the Discovery of Its Inhibition of Tumorigenesis to Its Use as a Therapeutic Agent. Cells. 2022;11(3):409. doi: 10.3390/cells11030409
Lee SY, Ko KS. Effects of S-Adenosylmethionine and Its Combinations With Taurine and/or Betaine on Glutathione Homeostasis in Ethanol–induced Acute Hepatotoxicity. J Cancer Prev. 2016;21(3):164-172. doi: 10.15430/ JCP.2016.21.3.164
Lee SY, Ko KS. Protective Effects of S-Adenosylmethionine and Its Combinations With Taurine and/or Betaine Against Lipopolysaccharide or Polyinosinic–polycytidylic Acid-induced Acute Hepatotoxicity. J Cancer Prev. 2016;21(3):152-163. doi: 10.15430/JCP.2016.21.3.152
Freedman BL, Danford CJ, Patwardhan V, et al. Treatment of Overlap Syndromes in Autoimmune Liver Disease: A Systematic Review and Meta–Analysis. J Clin Med. 2020;9(5):1449. doi: 10.3390/jcm9051449
Zhang H, Yang J, Zhu R, et al. Combination therapy of ursodeoxycholic acid and budesonide for PBC–AIH overlap syndrome: a meta–analysis. Drug Des Devel Ther. 2015;9:567-74. doi: 10.2147/DDDT.S74515
Leuschner M, Maier KP, Schlichting J, et al. Oral bude-sonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double–blind trial. Gastroenterology. 1999;117(4):918-925. doi: 10.1016/ s0016–5085(99)70351–3
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy. J Hepatol. 2023;79(3):768-828. doi: 10.1016/j.jhep.2023.03.006
Hernandez S, Hindorff LA, Morales J, et al. Patterns of pharmacogenetic variation in nine biogeographic groups. Clin Transl Sci. 2024;17(9):e70017. doi: 10.1111/cts.70017
Koturbash I, Yeager RP, Mitchell CA, et al. Botanical–in-duced toxicity: Liver injury and botanical–drug interac-tions. A report on a society of Toxicology Annual Meeting symposium. Regul Toxicol Pharmacol. 2024;153:105708. doi: 10.1016/j.yrtph.2024.105708
Unified clinical protocol of primary, secondary (specialized), medical aid. Autoimmune hepatitis]. Kyiv: Publishing House “KIM”; 2014:40.
Mack CL, Adams D, Assis N, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the Ameri-can Association for the Study of Liver Diseases. Hepatology. 2020;72(2):671-722. doi: 10.1002/hep.31065
Fedota O, Sadovnychenko I, Chorna L, et al. The Effects of Polymorphisms in One–carbon Metabolism Genes on Manifestation of Ichthyosis Vulgaris. Open Access Maced J Med Sci. 2021;9(A):291–7. doi: 10.3889/ oamjms.2021.6004
Lee KR, Gulnaz A, Chae YJ. Drug Interaction–Informed Approaches to Inflammatory Bowel Disease Management. Pharmaceutics. 2024;16(11):1431. doi: 10.3390/pharma-ceutics16111431
Moore CD, Roberts JK, Orton CR, et al. Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013;41(2):379-389. doi: 10.1124/ dmd.112.046318
Kilanczyk E, Banales JM, Wunsch E, et al. S–adenosyl-–L–methionine (SAMe) halts the autoimmune response in patients with primary biliary cholangitis (PBC) via antioxidant and S–glutathionylation processes in cholangiocytes. Biochim Biophys Acta Mol Basis Dis. 2020;1866(11):165895. doi: 10.1016/j.bbadis.2020.165895
Arumugam MK, Paal MC, Donohue TM Jr, et al. Beneficial Effects of Betaine: A Comprehensive Review. Biology (Basel). 2021;10(6):456. doi: 10.3390/biology10060456
Lawson–Yuen A, Levy HL. The use of betaine in the treatment of elevated homocysteine. Mol Genet Metab. 2006;88(3):201-207. doi: 10.1016/j.ymgme.2006.02.004
Maclean KN, Jiang H, Greiner LS, et al. Long-term betaine therapy in a murine model of cystathionine beta–synthase deficient homocystinuria: decreased efficacy over time reveals a significant threshold effect between eleva-ted homocysteine and thrombotic risk. Mol Genet Metab. 2012;105(3):395-403. doi: 10.1016/j.ymgme.2011.11.190
Fedota O, Babalian V, Ryndenko V, et al. Lactose tolerance and risk of multifactorial diseases on the example of gastrointestinal tract and bone tissue pathologies. Georgian Med News. 2020;(303):109-113.
Kalola UK, Ambati Sh. Budesonide. In: StatPearls. Treasure Island (FL): StatPearls https://www.ncbi.nlm.nih.gov/ books/NBK563201. Accessed August 28, 2023.
Pratt VM, Cavallari LH, Fulmer ML, et al. CYP3A4 and CYP3A5 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch
Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. J Mol Diagn. 2023;25(9):619-629. doi: 10.1016/j.jmoldx.2023.06.008
Dorofieieva V, Borysenko T, Fedota O. Diagnosis of liver cirrhosis on the background of mutations H63D of the HFE gene and H1069Q of the ATP7B gene associat-ed with Hemochromatosis and Wilson’s Disease (Clinical Case). Ukr J Med Biol Sports. 2022;3(37):120-126. doi: 10.26693/jmbs07.03.120
Bessone F, Hernandez N, Mendizabal M, et al. Serious liver injury induced by Nimesulide: an international collaborative study. Arch Toxicol. 2021;95(4):1475-1487. doi: 10.1007/s00204–021–03000–8
Pomey MP, Schaad B, Lasserre–Moutet A, et al. Towards a New Integrated Model for Taking Into Account the Experiential Knowledge of People With Chronic Diseases, Integrating Mediation, Therapeutic Education and Partnership: The Expanded Chronic Care Patient–Professional Partnership Model. Health Expect. 2024;27(5):e70054. doi: 10.1111/hex.70054
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
